Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amitriptyline hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

sentry medical pty ltd - 58993 - general-purpose medical foam padding - a non-sterile roll intended to be applied as a padding layer to a local area of the body for various preventative/therapeutic applications (e.g., in compression bandaging, padding under casts and splints, padding for anatomical depressions), typically over intact and healthy skin.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline 25 mg - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see  warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see  warnings  and  dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction.

United States - English - NLM (National Library of Medicine)

unit dose services - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline 25 mg - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery period

Australia - English - Department of Health (Therapeutic Goods Administration)

lenexa medical pty ltd - 43829 - pressure measurement/mapping system, anatomical - the len200 shall be used by clinicians and carers to provide information with respect to what position the patient is resting in and for how long they have been in such positions.